ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Scott M. Goldman
Francis P. Sutter
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marano, C. W.
Right arrow Articles by Mullin, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marano, C. W.
Right arrow Articles by Mullin, J. M.

Ann Thorac Surg 2000;70:1313-1318
© 2000 The Society of Thoracic Surgeons

Original article: cardiovascular

Plasma concentrations of soluble tumor necrosis factor receptor I and tumor necrosis factor during cardiopulmonary bypass

Colleen W. Marano, PhDa, Leah Ann Garulacan, BSa, Kathleen V. Laughlin, BSa, Lisa Igidbashian, MSNb, Candace Trace, RNb, Scott M. Goldman, MDb, Francis P. Sutter, DOb, George A. Reichard, Jr, PhDa, James M. Mullin, PhDa

a Lankenau Institute For Medical Research, Lankenau Hospital, Wynnewood, Pennsylvania, USA
b Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Lankenau Hospital, Wynnewood, Pennsylvania, USA

Address reprint requests to Dr Marano, Cytokines and Inflammation, Lankenau Institute for Medical Research, 100 Lancaster Ave, Wynnewood, PA 19096
e-mail: carusos{at}msn.com

Abstract

Background. Tumor necrosis factor-{alpha} (TNF) has been implicated in the development of postoperative morbidity after cardiopulmonary bypass for myocardial revascularization. Despite their postulated roles as modulators of TNF bioavailability, soluble TNF receptors have not been characterized in patients undergoing this procedure and is the focus of this study.

Methods. Soluble tumor necrosis factor receptor I (sTNFRI) and TNF were measured by immunoassay in plasma samples collected from 36 patients at events before, during, and after cardiopulmonary bypass.

Results. Plasma concentrations of sTNFRI averaged 1.39 ng/mL at the start of the operation. Preoperative sTNFRI concentrations were found to significantly correlate with a preoperative morbidity assessment score, age, duration of bypass, duration of supplemental oxygen, and length of hospital stay. Plasma sTNFRI increased in all of the patients during the procedure. Plasma concentrations of sTNFRI and TNF did not correlate at any time.

Conclusions. Preoperative measurement of sTNFRI could potentially serve as a reliable indicator for prophylactic treatment with an anti-TNF therapy. Such a therapeutic approach might help attenuate inflammatory processes thought to underlie postoperative morbidity associated with cardiopulmonary bypass.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2000 by The Society of Thoracic Surgeons.